Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 6/20 | 0.38 |
| ▸ | AKT1 | P31749 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302054 | 0.85 | MAPK1 (0.40) | GCGRMAPK14 | |
| SCHEMBL6304985 | 0.76 | ROCK1 (0.43) | AKT1MAPK14CYP11B1CYP11B2 | |
| SCHEMBL6302081 | 0.72 | MAPK13 (0.45) | CYP19A1AKT1MAPK14 | |
| SCHEMBL5256520 | 0.72 | GCGR (0.49) | GCGRMAPK14 | |
| SCHEMBL6078860 | 0.72 | GCGR (0.49) | GCGRMAPK14 | |
| SCHEMBL2907043 | 0.72 | CYP19A1 (0.68) | CYP19A1AKT1CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL28831872 | 0.72 | DYRK1A (0.38) | GCGRMAPK14CYP3A4CCNCCDK8 | |
| SCHEMBL6302201 | 0.69 | MAPK1 (0.47) | GCGRMAPK14CCNCCDK8 | |
| SCHEMBL14411785 | 0.68 | IMPDH2 (0.41) | AKT1 | |
| SCHEMBL6303910 | 0.68 | ROCK2 (0.43) | GCGRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-6852740-B2 | Pyrazole derivatives as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6503930-B1 | Treating cytokine-mediated diseases, such as inflammation | G.D. SEARLE & COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | CYP19A1 2115/4885GCGR 1885/4885AKT1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.